This will expand the original partnership agreement signed on April 2015, from four to five products, and adds a separate agreement which allows Vitruvias to buy in to a late stage, injectable project for $1.75 mil in upfront and milestone payments.
The addition of these two projects will strengthen the portfolios of both organizations by adding products in markets that currently exceed $600 mil dollars.
Both projects are in the final stages of development with the first ANDA tentatively scheduled for filing in the second quarter of 2017.
"We are thrilled to have the opportunity to further partner with Sunny Pharmtech on projects as sophisticated as these," said Carl Whatley, General Manager of Vitruvias.
"They have proven themselves to be an innovation-engine with regards to difficult-to-develop generics, and we are very fortunate to have found a partner with such a high level of development expertise."
Dr. Yon-Lian Wu, Sunny Pharmtech’s CEO and Chairperson, added, "I am delighted to announce the strengthening of the strategic partnership between Sunny Pharmtech and Vitruvias. These additional projects will allow us to address markets where the options for the patient are limited. We hope our eventual entry into these underserved markets will represent opportunities for patients who need these medicines, and our respective organizations."